AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Immunovant Inc (NASDAQ:IMVT)
18.2 USD
-0.590 3.140%Sponsored Reports
Loading...
| Previous Close (in USD) | 18.79 |
|---|---|
| Change | -0.590 3.140% |
| 52 W H/L (in USD) | 45.580/18.162 |
| EBITDA (in USD) | -253.368M |
| PE Ratio | -- |
| Volume | 432765 |
| Diluted Eps TTM | -1.78 |
| Total Assets (in USD) | 405.838M |
|---|---|
| Total Liabilities (in USD) | 43.344M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 376.532M |
| Market Cap (in USD) | 4,129.227 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Employees: 164
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Frank M. Torti M.B.A., M.D., MBA | Exec. Chairperson of the Board | 1979 |
| 2. | Dr. Peter Salzmann M.B.A., M.D. | CEO & Director | 1968 |
| 3. | Ms. Eva Renee Barnett M.B.A. | Chief Financial Officer | 1980 |
| 4. | Dr. William L. Macias M.D., Ph.D. | Chief Medical Officer | 1958 |
| 5. | Dr. Julia G. Butchko Ph.D. | Chief Devel. & Technology Officer | 1971 |
| 6. | Dr. Chau Cheng M.B.A., Ph.D. | VP of Investor Relations | NA |
| 7. | Mr. Mark S. Levine | Chief Legal Officer & Corp. Sec. | 1973 |
| 8. | Ms. Lauren Schrier M.B.A. | VP of Marketing | NA |
| 9. | Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 1979 |
| 10. | Dr. Peter Salzmann M.B.A., M.D. | CEO & Director | 1969 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.720 1.026% | 70.17 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.980 1.404% | 68.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.590 1.510% | 504.79 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+3.800 0.598% | 638.01 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-03-2023 | 31-03-2022 | 31-03-2021 | 31-03-2020 | 31-03-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -210.951M | -156.814M | -107.789M | -66.291M | -0M |
| Minority Interest | - | - | - | - | - |
| Net Income | -210.96M | -156.73M | -107.431M | -66.388M | -0M |
| Selling General Administrative | 48.019M | 54.225M | 39.513M | 18.151M | 2.692M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 0.193M | 0.126M | 0.065M | 0.021M | - |
| Ebit | -198.469M | -156.159M | -107.789M | -65.666M | -0M |
| Ebitda | -198.276M | -156.033M | -107.724M | -65.645M | -0M |
| Depreciation And Amortization | 0.193M | 0.126M | 0.065M | 0.021M | - |
| Operating Income | -198.469M | -156.159M | -107.789M | -65.666M | -0M |
| Other Operating Expenses | 208.276M | 156.033M | 108.117M | 66.078M | 0M |
| Interest Expense | 12.482M | 0.655M | 0M | 0.625M | 0M |
| Tax Provision | 0.009M | -0.084M | -0.358M | 0.097M | - |
| Interest Income | 7.578M | - | - | 0.625M | - |
| Net Interest Income | 7.578M | - | 0M | -0.625M | - |
| Income Tax Expense | 0.009M | -0.084M | -0.358M | 0.097M | 0.019M |
| Total Revenue | 0M | 0M | 0M | 0M | - |
| Total Operating Expenses | 208.276M | 156.033M | 108.117M | 66.078M | 0M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | -12.482M | -0.655M | 0.328M | -0.625M | -0.155M |
| Net Income From Continuing Ops | -210.96M | -156.73M | -107.431M | -66.388M | -28.599M |
| Net Income Applicable To Common Shares | -210.96M | -156.73M | -107.431M | -66.388M | -28.599M |
Balance Sheet
(Currency in USD)| Breakdown | 31-03-2023 | 31-03-2022 | 31-03-2021 | 31-03-2020 | 31-03-2019 |
|---|---|---|---|---|---|
| Total Assets | 405.838M | 515.564M | 412.489M | 109.387M | 0.405M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 26.916M | 6.253M | 8.312M | 5.46M | 0.08M |
| Total Liab | 43.344M | 45.739M | 21.009M | 15.318M | 0.38M |
| Total Stockholder Equity | 362.494M | 469.825M | 391.48M | 94.069M | 0.025M |
| Other Current Liab | 40.771M | 24.746M | 15.16M | 14.128M | 0.08M |
| Common Stock | 0.013M | 0.012M | 0.01M | 0.005M | 0M |
| Capital Stock | 0.013M | 0.012M | 0.01M | 0.005M | 0M |
| Retained Earnings | -566.347M | -355.387M | -198.657M | -91.226M | -0M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 0.246M | 1.195M |
| Cash | 376.532M | 493.817M | 400.146M | 100.571M | 0.325M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 43.297M | 44.52M | 18.771M | 15.318M | 0.38M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -375.312M | -491.453M | -396.729M | -100.571M | -0.025M |
| Short Term Debt | 1.173M | 1.145M | 1.179M | - | 0.3M |
| Short Long Term Debt | - | - | - | - | 0.3M |
| Short Long Term Debt Total | 1.22M | 2.364M | 3.417M | - | 0.3M |
| Other Stockholder Equity | 927.976M | 824.796M | 590.425M | 185.306M | 0.025M |
| Property Plant Equipment | 0.333M | 0.33M | 0.201M | 0.065M | 0.054M |
| Total Current Assets | 404.333M | 512.931M | 409.006M | 109.076M | 0.325M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 0.885M | 12.861M | 0.548M | 3.045M | 2.962M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 1.353M | 18.629M | 2.432M | 1.19M | 0.206M |
| Accumulated Other Comprehensive Income | 0.852M | 0.404M | -0.298M | -0.016M | - |
| Non Currrent Assets Other | - | - | - | 0.246M | 0.08M |
| Non Current Assets Total | 1.505M | 2.633M | 3.483M | 0.311M | 0.08M |
| Capital Lease Obligations | 1.22M | 2.364M | 3.417M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-03-2023 | 31-03-2022 | 31-03-2021 | 31-03-2020 | 31-03-2019 |
|---|---|---|---|---|---|
| Investments | -0.197M | -0.254M | -0.21M | -0.031M | - |
| Total Cashflows From Investing Activities | -0.197M | -0.254M | -0.21M | -0.031M | -0.052M |
| Total Cash From Financing Activities | 70.885M | 200.129M | 383.112M | 146.974M | 0.325M |
| Net Income | -210.96M | -156.73M | -107.431M | -66.388M | -0M |
| Change In Cash | -117.285M | 93.671M | 299.575M | 93.586M | 0.325M |
| Begin Period Cash Flow | 493.817M | 400.146M | 100.571M | 6.985M | - |
| End Period Cash Flow | 376.532M | 493.817M | 400.146M | 100.571M | 0.325M |
| Total Cash From Operating Activities | -188.193M | -106.112M | -83.327M | -53.357M | -28.547M |
| Depreciation | 0.193M | 0.126M | 0.065M | 0.021M | 0.01M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 70.885M | 200M | 385.206M | 0.001M | 0.025M |
| Other Cashflows From Financing Activities | 0.385M | 200.129M | 66.519M | 151.974M | 0.3M |
| Capital Expenditures | 0.197M | 0.254M | 0.21M | 0.031M | 0.052M |
| Change In Working Capital | -10.853M | 15.142M | 4.566M | 4.806M | 0M |
| Other Non Cash Items | 1.131M | 1.106M | 0.933M | 1.241M | - |
| Free Cash Flow | -188.39M | -106.366M | -83.537M | -53.388M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Growth Compy Commingled Pl O | 11 months ago | 3198246 |
| 2. | Fidelity Growth Company Fund | 11 months ago | 2370591 |
| 3. | SPDR® S&P Biotech ETF | 11 months ago | 2246769 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 11 months ago | 2106805 |
| 5. | Vanguard Small Cap Index | 11 months ago | 1662981 |
| 6. | iShares Russell 2000 ETF | 11 months ago | 1260540 |
| 7. | Vanguard Small Cap Value Index Inv | 11 months ago | 1115751 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 11 months ago | 842520 |
| 9. | Fidelity Growth Company K6 | 11 months ago | 820169 |
| 10. | T. Rowe Price New Horizons | 11 months ago | 802858 |
| 11. | US Small-Cap Growth II Equity Comp | 11 months ago | 802858 |
| 12. | American Funds SMALLCAP World A | 11 months ago | 780367 |
| 13. | Fidelity Select Biotechnology | 11 months ago | 726843 |
| 14. | Pictet-Biotech P USD | 1 year ago | 681635 |
| 15. | Fidelity Series Growth Company | 11 months ago | 571000 |
| 16. | Franklin Biotechnology Discv A(acc)USD | 11 months ago | 560870 |
| 17. | Fidelity Small Cap Index | 1 year ago | 551625 |
| 18. | Lord Abbett Developing Growth A | 11 months ago | 486055 |
| 19. | iShares Russell 2000 Growth ETF | 11 months ago | 455225 |
| 20. | Pictet-Global Megatrend Sel I USD | 1 year ago | 452210 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 1 year ago | 7875822 |
| 2. | Vanguard Group Inc | 11 months ago | 6478304 |
| 3. | BlackRock Inc | 1 year ago | 4530716 |
| 4. | State Street Corporation | 1 year ago | 3216376 |
| 5. | Perceptive Advisors LLC | 11 months ago | 2963212 |
| 6. | Armistice Capital, LLC | 11 months ago | 2164000 |
| 7. | Alpine Partners VI, LLC | 11 months ago | 1882704 |
| 8. | T. Rowe Price Associates, Inc. | 11 months ago | 1862043 |
| 9. | Viking Global Investors LP | 11 months ago | 1809172 |
| 10. | Logos Global Management LP | 11 months ago | 1775000 |
| 11. | Woodline Partners LP | 11 months ago | 1289504 |
| 12. | Geode Capital Management, LLC | 1 year ago | 1272966 |
| 13. | Fred Alger Management, LLC | 11 months ago | 1271762 |
| 14. | Pictet Asset Manangement SA | 11 months ago | 1265298 |
| 15. | Nuveen Asset Management, LLC | 1 year ago | 1227266 |
| 16. | Rock Springs Capital Management LP | 11 months ago | 1150123 |
| 17. | COMMODORE CAPITAL LP | 1 year ago | 1000000 |
| 18. | Capital Research Global Investors | 11 months ago | 976237 |
| 19. | Redmile Group, LLC | 11 months ago | 969621 |
| 20. | Goldman Sachs Group Inc | 1 year ago | 916262 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
